Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jill Gilbert

Showing results (41-50 of 78) with videos related to

Pageof 8
Sort By:
Cancer|May 20, 2008
Phase II trial of irinotecan plus cisplatin in patients with recurrent or metastatic squamous carcinoma of the head and neckJill Gilbert, Anthony Cmelak, Yu Shyr, et al.
Oral Oncology|August 18, 2018
Induction chemotherapy with carboplatin, nab-paclitaxel and cetuximab for at least N2b nodal status or surgically unresectable squamous cell carcinoma of the head and neckJared Weiss, Jill Gilbert, Allison Mary Deal, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 13, 2014
A phase I study of continuous oral dosing of OSI-906, a dual inhibitor of insulin-like growth factor-1 and insulin receptors, in patients with advanced solid tumorsIgor Puzanov, Colin R Lindsay, Laura Goff, et al.
Oral Oncology|December 26, 2015
A phase I study afatinib/carboplatin/paclitaxel induction chemotherapy followed by standard chemoradiation in HPV-negative or high-risk HPV-positive locally advanced stage III/IVa/IVb head and neck squamous cell carcinomaChristine H Chung, Michelle A Rudek, Hyunseok Kang, et al.
The Oncologist|July 22, 2024
A review of mitotane in the management of adrenocortical cancerJaydira Del Rivero, Tobias Else, Julie Hallanger-Johnson, et al.
Oral Oncology|March 9, 2022
Mature follow up of induction chemotherapy with carboplatin, nab-paclitaxel, cetuximab in head and neck squamous cell carcinomaSiddharth Sheth, Jill Gilbert, Allison Mary Deal, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 1, 2009
A phase I dose-finding study of 5-azacytidine in combination with sodium phenylbutyrate in patients with refractory solid tumorsJianqing Lin, Jill Gilbert, Michelle A Rudek, et al.
Clinical Lung Cancer|June 27, 2020
Clinical Activity and Safety of Atezolizumab in a Phase 1 Study of Patients With Relapsed/Refractory Small-Cell Lung CancerAnne C Chiang, Lecia Van Dam Sequist, Jill Gilbert, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 10, 2015
A Phase I Study of CUDC-101, a Multitarget Inhibitor of HDACs, EGFR, and HER2, in Combination with Chemoradiation in Patients with Head and Neck Squamous Cell CarcinomaThomas J Galloway, Lori J Wirth, Alexander D Colevas, et al.
Head & Neck|July 24, 2009
Reliability and validity of the Vanderbilt Head and Neck Symptom Survey: a tool to assess symptom burden in patients treated with chemoradiationBarbara A Murphy, Mary S Dietrich, Nancy Wells, et al.
Pageof 8

Showing results (41-50 of 78) with videos related to

Sort By:
Pageof 8
Cancer|May 20, 2008
Phase II trial of irinotecan plus cisplatin in patients with recurrent or metastatic squamous carcinoma of the head and neckJill Gilbert, Anthony Cmelak, Yu Shyr, et al.
Oral Oncology|August 18, 2018
Induction chemotherapy with carboplatin, nab-paclitaxel and cetuximab for at least N2b nodal status or surgically unresectable squamous cell carcinoma of the head and neckJared Weiss, Jill Gilbert, Allison Mary Deal, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 13, 2014
A phase I study of continuous oral dosing of OSI-906, a dual inhibitor of insulin-like growth factor-1 and insulin receptors, in patients with advanced solid tumorsIgor Puzanov, Colin R Lindsay, Laura Goff, et al.
Oral Oncology|December 26, 2015
A phase I study afatinib/carboplatin/paclitaxel induction chemotherapy followed by standard chemoradiation in HPV-negative or high-risk HPV-positive locally advanced stage III/IVa/IVb head and neck squamous cell carcinomaChristine H Chung, Michelle A Rudek, Hyunseok Kang, et al.
The Oncologist|July 22, 2024
A review of mitotane in the management of adrenocortical cancerJaydira Del Rivero, Tobias Else, Julie Hallanger-Johnson, et al.
Oral Oncology|March 9, 2022
Mature follow up of induction chemotherapy with carboplatin, nab-paclitaxel, cetuximab in head and neck squamous cell carcinomaSiddharth Sheth, Jill Gilbert, Allison Mary Deal, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 1, 2009
A phase I dose-finding study of 5-azacytidine in combination with sodium phenylbutyrate in patients with refractory solid tumorsJianqing Lin, Jill Gilbert, Michelle A Rudek, et al.
Clinical Lung Cancer|June 27, 2020
Clinical Activity and Safety of Atezolizumab in a Phase 1 Study of Patients With Relapsed/Refractory Small-Cell Lung CancerAnne C Chiang, Lecia Van Dam Sequist, Jill Gilbert, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 10, 2015
A Phase I Study of CUDC-101, a Multitarget Inhibitor of HDACs, EGFR, and HER2, in Combination with Chemoradiation in Patients with Head and Neck Squamous Cell CarcinomaThomas J Galloway, Lori J Wirth, Alexander D Colevas, et al.
Head & Neck|July 24, 2009
Reliability and validity of the Vanderbilt Head and Neck Symptom Survey: a tool to assess symptom burden in patients treated with chemoradiationBarbara A Murphy, Mary S Dietrich, Nancy Wells, et al.
Pageof 8